Creating a CAR-T Cell Presentation Tool for the Emergency Room

Chimeric antigen receptor T cell (CAR-T cell) therapy has become a promising treatment for children with acute lymphoblastic leukaemia (ALL) and Non-Hodgkin lymphoma (NHL). Cytokine release syndrome (CRS) and Immune effector cell associated neurotoxicity syndrome (ICANS) are well-documented serious side-effects of CAR-T cell therapy, and early recognition, intervention and aggressive supportive therapy is paramount.Tociluzimab is the mainstay of treatment for moderate to severe CRS, with early administration essential.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Laura R.M. Chapman, Bridget Smith, Karen McCleary, Richard Mitchell, Tracey A. O'Brien Tags: 601 Source Type: research